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Abstract
Background: Asbestos related diseases include a number of conditions due to inhalation of asbestos fibres at work, at 
home or in the environment, such as pleural mesothelioma, asbestosis and calcified pleural plaques. Few 
epidemiological studies have established the incidence of asbestos related diseases in our area. The present proposal is 
based on a retrospective study externally funded in 2005 that is currently taking place in the same area and largely 
carried out by the same research team.
The aim of the study is to achieve a comprehensive and coordinated detection of all new cases of Asbestos Related
Diseases presenting to primary care practitioners.
Methods/design: This is a multicentre, multidisciplinary and pluri-institutional prospective study.
Setting
12 municipalities in the Barcelona province within the catchment area of the health facilities that participate in the
study.
Sample
This is a population based study, of all patients presenting with diseases caused by asbestos in the study area.
Measurements
A clinical and epidemiological questionnaire will be filled in by the trained researchers after interviewing the patients
and examining their clinical reports.
Discussion: Data on the incidence of the different Asbestos Related Diseases in this area will be obtained and the most 
plausible exposure source and space-time-patient profile will be described. The study will also improve the 
standardization of patient management, the coordination between health care institutions and the development of 
preventive activities related with asbestos exposure and disease.
Background
H umans have used asbestos for centuries. W e find the
first reference at around 2,500 BC in cremation ceremo-
nies where it is described as a material that burns like
wood but does not get burned down when used with oil.
The two essential characteristics of asbestos are reflected
in this historical note: incombustibility and thermal isola-
tion properties that stand temperatures up to 900°C.
Thanks to these properties, we find asbestos in over
3,000 different applications in most industrial sectors
[1,2]. In Barcelona province, the jobs associated with the
highest risk are workers at fibrocement plants, painters,
carriers of asbestos materials and construction workers
[3].
Asbestos is classified into serpentine (curly fibres) and
amphibole (straight fibres). Chrysotile or white asbestos
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belongs to the serpentine group and is the most wide-
spread, amounting to 90% of all industrial asbestos. The
chemical structure consists of a silicate compound of dif-
ferent metals (iron, magnesium and calcium) with a
fibrous external appearance and a basic physical unit of
50-100 by 0.5-3 μm. It is therefore a true microscopic
needle with the ability to enter the aerodynamic structure
of the bronchial tree and to reach the smallest and most
distal bronchioles and alveoli close to the pleura, thus
producing a direct lesion to the lateral and basal lung
parenchyma.
Asbestos can also spread via the lymphatic system [2].
Once the asbestos fibres are deposited in the lung, cells
are destroyed, fibrosis and perialveolar and bronchiolar
scarring takes place (pulmonary asbestosis), ultimately
causing breathing difficulty.
Asbestos Related Diseases (ARD) is a group of 10 con-
ditions that affect mainly the respiratory system, caused
by the inhalation and subsequent deposit of asbestos
fibres in the pulmonary parenchyma. ARD are divided
into malignant (pleural mesothelioma, peritoneal meso-
thelioma, asbestos-related bronchopulmonary carci-
noma, and other neoplasms) and non-malignant, in
agreement with the guidelines with a broader worldwide
consensus [4,5]. The non-malignant ARD comprise dis-
eases of the lung parenchyma (asbestosis or interstitial
lung fibrosis), of the pleura (isolated pleural plaques, dif-
fuse pleural fibrosis or pleural thickening and benign
pleural effusion), and of the bronchi, with chronic bron-
chial obstruction and round atelectasis.
Asbestos toxicity is related to its fibrous structure, since
it has been shown that pulverized asbestos does not cause
disease [6]. Short or low intensity exposure to asbestos
does not exclude the possibility of ARD, since there are
individual susceptibility factors to asbestosis still poorly
understood [7]. The study of risk factors can be hindered
by the long latency period between inhalation and clinical
disease.
In addition to its fibrogenic properties, asbestos is a
first-level carcinogen [2]. The most accepted oncological
model is the dose-response without a safety level [8].
The fibrogenic and carcinogenic properties are related,
particularly in the amphibole type of asbestos. Its role has
been shown in the development of mesothelioma and
other pulmonary neoplasms, where it would act as a co-
carcinogenic agent [9]. The diagnosis of malignant meso-
thelioma requires histological and histochemical tech-
niques to differentiate it from metastasis from other
cancers. The risk of suffering from a malignant mesothe-
lioma increases with age, and depends on time of expo-
sure. In turn, these factors are related to the level of
exposure, continuity of exposure, and latency period [10].
The main risk factor to develop ARD is work exposure,
usually in the past, due to inhalation of asbestos fibres.
However, not everybody that has been or is in contact
with asbestos develops ARD. One of the main difficulties
in the study of ARD is the lack of information related to
exposure history in the primary care and hospital clinical
records of pulmonary fibrosis and lung cancer patients.
This factor, coupled with the late age at diagnosis due to
the time gap between exposure and clinical manifesta-
tions, explains that a significant number of ARD cases are
not considered a work-related disease [10]. Worldwide, a
large number of ARD are not considered or notified as a
work-related disease [11]. In Spain, asbestosis, asbestos-
related lung cancer and mesothelioma are classified as
work-related diseases in the Royal Decree 1995/1978 of
12th of May [12]. The scarce notification of these cases as
work-related conditions contributes to the lack of knowl-
edge of the real incidence of ARD.
On the other hand, the non-work related exposures
that can cause ARD are the consequence of fibre inhala-
tion when living near an asbestos source, living together
with an asbestos worker that brought the asbestos fibres
in the work clothes, the domestic use of products manu-
factured with asbestos that are in a poor condition, and
finally simple environmental exposure. This last exposure
possibility has been studied more deeply in the case of
mesothelioma than in asbestos-related lung cancer [13-
15]. The incidence of cases of benign ARD, asbestosis
comprised, of environmental origin has hardly been
approached.
Tobacco consumption is a predisposing factor for ARD.
Smokers exposed to asbestos are at higher risk to develop
radiologic signs of asbestosis than non-smokers. In turn,
a s b e s t o s i s  i s  a  r i s k  f a c t o r  o f  l u n g  c a n c e r .  T h e r e f o r e ,
tobacco consumption would be a non-predisposing con-
comitant risk factor that has a modulating effect between
asbestosis and lung cancer risk [9]. In Spain, around 4%
lung cancers cases are related to asbestos work exposure
in synergy with tobacco consumption [16]. No associa-
tion has been found between tobacco consumption and
mesothelioma [2].
The clinical presentation of ARD ranges from a sub-
clinical, asymptomatic stage, the casual finding of a dry
and persistent cough, to a severe and chronic or acute
dyspnoea, in the case of mesothelioma. Expectoration,
bronchial obstruction and poor resolution of respiratory
symptoms are not pure manifestations of asbestos dis-
ease, but of its associated bronchial component. The first
descriptive studies carried out 25 years ago in the indus-
trial area of Barcelona indicated that up to 25% of
exposed workers could present with ARD [17]. Asbestosis
can also be diagnosed when a routine chest X-ray detects
irregular, little opacities [9].
The definitive diagnosis of ARD is reached by histology,
through the cytological detection of asbestos bodies. In
most cases this test is not available and the diagnosis isRosell-Murphy et al. BMC Public Health 2010, 10:203
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based on imaging, a history of exposure with an appropri-
ate latency period, and ruling out other possibilities [5].
The imaging techniques can show a diffuse thickening
of the pleura (mainly visceral), pleural plaques (mainly
parietal, calcified or not calcified), massive or partial
pleural effusion, pleural masses and even a bibasilar hon-
eycombing pattern, characteristic of pulmonary fibrosis
[6]. The high-resolution CT scan is more accurate and
sensitive than conventional X-ray and conventional CT
scan, which has a low predictive value of 50%.
The only method of ARD primary prevention is to
avoid the inhalation of asbestos fibres. To achieve this,
the industry that manipulates this product is subjected to
strict safety regulations and constant controls to elimi-
nate every possibility of respiratory or topical exposure.
Asbestos use is currently banned in the European Union
with the aim to reach a 0 level of exposure. However, it
needs to be taken into account that there are still thou-
sands of tons of installed asbestos in the European Union
territory.
Secondary prevention is based on an early diagnosis
carried out by the units responsible for the surveillance of
health of workers exposed to asbestos, and of the exposed
general population [18], the establishment of care and
rehabilitation measures, and a change of workplace.
According to the Protocol of Health Surveillance Specific
for Asbestos [19], exposed workers need to follow bian-
nual checkups. Tertiary prevention is the treatment and
rehabilitation of the lung function damaged by the ARD.
ARD, particularly the non-malignant forms, is a cause
of morbidity and mortality that has been scarcely studied
worldwide. Its incidence on the population of the area of
this study is unknown.
The latency period between the inhalation of asbestos
fibres and ARD is estimated to be around 15 years. It is
accepted that the "spontaneous" incidence of mesothe-
lioma is extremely rare, less than 1 new case for one mil-
lion inhabitants per year [20]. In Western Europe the
incidence was around 1 per million until the middle of
the 1950s, but currently it has increased to 3 per million
per year [6]. No data on the incidence of non-malignant
ARD exist.
In Barcelona province the incidence of mesothelioma,
estimated from mortality data of residents, is 8.3 cases/
million inhabitants/year in men, and 4.7 cases/million
inhabitants/year in women, in 1993 [21,22]. More
recently [23] the global ARD incidence in the area of
study was 9.5 cases/100.000/year. In some towns these
figures are much higher: Cerdanyola and Ripollet 35.5
cases/100.000 inhabitants/year. No more data are avail-
able and there is a lack of studies oriented to the eventual
clinical changes in the ARD follow up.
Incidence data on other ARD in this area are scarce,
since it is very rare to register them as a mortality cause,
and no prospective studies such as ours exist. The real
morbidity and mortality impact of asbestos exposure and
the epidemiological and clinical characteristics of the
incident cases in this area are not known, but our study is
based on the hypothesis that the incidence of non-malig-
nant ARD is also significant.
From 1907 until 1997 one of the larger fibrocement
plants in Spain operated in the town of Cerdanyola del
Vallès. One of the main components of fibrocement is
asbestos. The workers and the general public of this
highly populated area have been exposed to asbestos for a
long period, and probably they still are due to continued
exposure to environmental traces of this material. The
identification of increasing numbers of ARD, initially
among the fibrocement plant workers but also of other
asbestos handling plants, and in the general population in
this area of the Barcelona province, has alerted our
research team. The current real impact of ARD in this
area and the characteristics of the affected people remain
unknown.
Of all cases of ARD, an important proportion is related
to work exposure. Other ARD cases suggest a non-work
or "passive" exposure. This could be just living with or
having close contact with a worker that brings asbestos
fibres home after finishing the day's work. There are also
environmental causes, such as living close to an asbestos
source or an industrial asbestos deposit (vicinity). The
use of damaged domestic utensils that contain asbestos
merits also mention.
In the Brescia province in Italy a register of mesothe-
lioma cases has been established to identify the cases
related to work exposure so that they can receive the
appropriate benefit [24].
The proportion of cases of mesothelioma attributed to
domestic or environmental exposure in the Barcelona
province is 26% [15]. For the rest of ARD the percentage
attributable to direct work exposure versus passive expo-
sure is unknown. None of the studies published to date
have include all types of malignant and non-malignant
ARD as we aim in our study.
The clinical experience of the study members suggests
that most ARD cases are found within the Catalan Health
Institute network of primary care and medical specialists,
facilitating a comprehensive detection of new cases.
The extended latency period until the onset of symp-
toms means that even if the disease is mainly work
related, most cases will be suspected in the aging popula-
tion, retired people very often, and in the context of the
daily routine of the general practitioner.
Therefore, we propose to carry out a prospective, clini-
cal -epidemiological study based on the comprehensive
(all cases), full (all information of every case) and coordi-
nated (among all centres) of the incident cases of ARD
between January 2006 and December 2008, with theRosell-Murphy et al. BMC Public Health 2010, 10:203
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objective to measure the incidence of ARD in this area, to
describe the characteristics of the exposure, and to inves-
tigate the space, time and patient profile of the people
affected by asbestos.
Previous studies of ARD in Catalonia focus only on
mesothelioma incidence, studying mortality. Our group
aims at broadening this population-based medical
research to the incidence of the other 9 manifestations of
ARD to obtain the morbidity and mortality impact of
asbestos in the study population.
The active search and investigation of the suspected
cases in our area will contribute to its early identification
and will raise awareness of this group of diseases among
the professionals. Also, they will be able to improve the
diagnosis and follow-up of these patients. Concerning
health managers and authorities, this information will
contribute to plan the future allocation of health
resources.
Hypothesis
The first hypothesis considers that asbestos has played an
important role in the industrial development of the study
area and therefore it continues to cause a poorly defined
and quantified morbidity and mortality by means of a
current or past inhalation of asbestos fibres. The expo-
sure can be direct (work exposure) or passive (domestic
or environmental) or both.
The second hypothesis states that ARD are underre-
ported. We believe that the notification of work related
respiratory diseases caused by asbestos in our area is
underreported, and it also affects mortality statistics
because of the underreporting of ARD as a cause in death
certificates.
The third hypothesis considers the possibility of popu-
lation clusters of incident ARD cases in the study area
that could be compared with one another and that would
generate new hypothesis.
Objectives
Main objective
The main objective of the study is to measure the inci-
dence rates and the adjusted mortality rates of the 10 ill-
nesses that constitute ARD in the study area. The
descriptive mortality and morbidity profile will be
adjusted by age and sex, exposure variables and source of
exposure (work, environmental or both). Also, the rela-
tionship between length of exposure, latency between
exposure and first respiratory symptoms, disease diagno-
sis and decease during the follow up will be studied.
Specific objectives
-To quantify comprehensively the incident cases and to
describe the associated clinical and epidemiological vari-
ables.
-To quantify the magnitude of underreporting of ARD
in the notified work-related morbidity.
-To quantify the magnitude of ARD underreporting in
the death certificates by looking at the mortality statistics
of the people whose cause of death was any of the 10 ill-
nesses that constitute ARD.
- The possible detection of geographical clusters of
ARD incident cases will contribute to the understanding
of the ARD impact on the study population.
Methods/Design
1. Study area: consists of 12 municipalities in the Barce-
lona province within the catchment area of the health
facilities that participate in the study: Cerdanyola del
Vallès, Ripollet, Barberà del Vallès, Badia del Vallès,
Sabadell, Sant Quirze del Vallès, Santa Perpetua de la
Mogoda, Polinyà, Palau de Plegamans-Solità., Castellar
del Vallès, Sentmenat and Sant Llorenç Savall. All 12
municipalities refer the patients to the hospital that par-
ticipates in the project. Nearby towns with a different
referral hospital are excluded.
2. Study population: anyone who lives in any of the 12
municipalities of the study area and consents to partici-
pate in the study. The estimated population is 350,000
inhabitants.
3. Study network setting: the study is framed within
the area covered by all primary care teams in these 12
municipalities. All these primary care teams belong to
one public health provider organization: the Catalan
Institute of Health (CIH) and are fully computerised.
These teams work with the disease classification of the
CIH and refer their patients to the only referral hospital
centre in the area, the Consorci Hospitalari Parc Taulí,
which belongs to the Public Hospital Network. The only
referral Work Health Unit of this area does also partici-
pate in the study.
4. Design: clinical -epidemiological, longitudinal, pro-
spective study of incident cases diagnosed with any of the
10 diseases that constitute ARD from 1/1/2006 to 31/12/
2008.
5. ARD definition: ARD is a group of 10 conditions
that affect mainly the respiratory system, caused by the
inhalation and subsequent deposit of asbestos fibres.
According to the guidelines with a broader worldwide
consensus [4] ARD are divided in two groups: malignant
ARD (pleural mesothelioma, peritoneal mesothelioma,
asbestos-related pulmonary carcinoma, and other neo-
plasms) and non-malignant ARD. The non-malignant
ARD comprise diseases of the lung parenchyma (asbesto-
sis or interstitial lung fibrosis), of the pleura (isolated
pleural plaques, diffuse pleural fibrosis or pleural thick-
ening and benign pleural effusion), and of the bronchi
(chronic bronchial obstruction and round atelectasis).Rosell-Murphy et al. BMC Public Health 2010, 10:203
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6. ARD case definition: cases are defined as any per-
son within the study area (section 1) first diagnosed with
at least one of the ARD (section 5) between 1/1/2006 and
31/12/2008, in accordance with the diagnostic criteria
internationally accepted, [4] and who consents to partici-
pate in the study. If the patient or his/her family do not
sign the informed consent some basic data will still be
collected and registered. The basic data for this study are:
date of birth, sex, diagnosis and town of current resi-
dence. It allows to preserve anonymity and to avoid dupli-
cations. All cases with confirmed informed consent that
are lost to follow up will be registered and the cause of the
loss recorded.
For the diagnosis of ARD, fulfilment of the three follow-
ing conditions is considered necessary and sufficient: a)
either imaging or pathology techniques show that the
patient has a lesion compatible with ARD in the respira-
tory system; b) a sufficient latency period between a work
and/or environmental asbestos exposure and/or proof of
one or two physiopathological markers of exposure (pleu-
ral plaques detected by imaging or presence of asbestos
bodies in the bronchoalveolar lavage or in a cytology
sample) and c) exclusion of other possible causes of the
current disease.
7. Study variables:  Appendix 1 describes the study
variables. Data are collected by the specifically trained
research team by means of a direct interview to the
patient or to a close relative.
8. Circuit of case detection and selection: awareness
and training workshops for the detection of ARD possible
cases will be organised for the general practitioners of the
study area. The circuit starts when a possible new case is
detected. The general practitioner refers it to the respira-
tory medicine specialist of the area for diagnostic confir-
mation, then the ICD 10 codes concerning ARD (J61;
J92.0; C45) are incorporated in the computerised clinical
record of the patient, and a study team physician is noti-
fied.
In the primary care teams of Cerdanyola del Vallès, Rip-
ollet, Barberà del Vallès and Badia del Vallès there is a
study assigned doctor that will receive the clinical data of
the confirmed case from the general practitioner. This
assigned doctor is a team researcher trained to collect the
variables of the identification file. He/she has an inter-
view with the patient, and if the case fulfils the conditions
in sections 1, 2, 3, 5 and 6 the patient is given information
about the study (see Appendix 2) and is asked to volun-
tarily participate. If the patient accepts the informed con-
sent form must be signed (see Appendix 3).
Subsequently the variables obtained by direct interview
and through the available clinical information are regis-
tered in the identification file. When the file is completed
it is sent to the respiratory medicine specialist who centr-
alises and carries out the last quality control of all the
study data. This specialist can request additional medical
tests and consultations, confirms the diagnosis, checks
the identification file, starts the follow-up and refers back
the patient to his/her family physician with the clinical
information and future management recommendations.
The specialist will also send the identification file to the
person in charge of entering the data in the single data-
base.
The Primary Care Teams in the towns of Sabadell, Sant
Quirze del Vallès, Santa Perpetua de la Mogoda, Polinyà,
Palau de Plegamans-Solità, Castellar del Vallès, Sentme-
nat and Sant Llorenç Savall are also fully computerised,
although there is not a doctor allocated to each location
because the retrospective study indicates that probably
there will be less cases here than in the Cerdanyola-Ripol-
let area.
Here the detection of cases will take place in primary
care, and will be confirmed in the Respiratory Medicine
Department of the referral hospital (Consorci Hospitalari
Parc Taulí). A study team physician and member of the
referral hospital will be in close contact with the Respira-
tory and Outpatient Departments of the hospital to facili-
tate the collection of the epidemiological variables of the
patients. The epidemiological files will be sent to the
ARD specialist, who will centralise and complete the
information, and will send them to be included in the
project database.
A study team member, respiratory medicine specialist
in the Hospital Vall d'Hebron in Barcelona, will identify
the cases in the study area that are not captured by the
established primary care circuit.
If there are doubts about work exposure in any of the
cases, the general practitioner as well as the assigned doc-
tors in the study area can refer it to the referral Work
Health Unit, where the doctor in charge will undertake a
thorough history and, if needed, will be able to obtain fur-
ther information on the factories where the patient has
worked. The Work Health Unit will send a report to the
assigned doctor with the relevant data and the conclu-
sions on the work aetiology of the case.
9. Collected data entry in a single database: one of
the research team members and the fieldwork assistant
will double-entry the variables of the Identification File
(see Appendix 1) in the project database to validate the
information and for an optimum quality control. A hard-
c o p y  o f  e v e r y  f i l e  w i l l  b e  s t o r e d  f o r  f u t u r e  c h e c k s ,
together with the informed consent form.
10. Level of detection of cases:  an important chal-
lenge of the study is the comprehensive detection of inci-
d e n t  c a s e s ,  w h i c h  w i l l  b e  o b t a i n e d  t h r o u g h  t h e
optimization of the circuits described in section 8. For
that, the ability of the research team to train and raise
awareness among the colleagues in primary care in ARD
detection is considered essential. A minimum of twoRosell-Murphy et al. BMC Public Health 2010, 10:203
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training and reminder sessions will take place with each
PCT of the study area just before the beginning of the
study, and at least another at the end to present the
results and analyse future implications. The Work Health
Unit is the referral point of all PCT in the area for the
work related pathology, and it actively participates in the
sensitization of the family doctors to detect and notify
suspected ARD cases.
The Consorci Hospitalari Parc Taulí is the referral hos-
pital for the whole study area, and besides furthering the
study of the ARD cases for diagnostic confirmation, new
ARD cases can be detected in its Emergency or Respira-
tory Medicine Outpatient Departments. The fieldworker
will undertake every three months a comprehensive
search for every computerised new case of primary care
and hospital discharge reports with the relevant ICD 10
codes (J61; J92.0; C45). A member of the research team
will support the fieldworker to ensure the uniformity and
quality of the information.
11. Estimate of the detected new cases figures: this is
a population based study, of which of the 10 diseases that
constitute ARD, we only know the incidence rate of
mesothelioma for Barcelona province. Due to the lack of
known rates for the other ARD, the final size calculation
was based on the actual frequency of ARD new cases in
primary care in the study area. We consider that it is very
difficult to estimate the total number of incident cases
that we will find, but we are confident that the three years'
duration of the study will allow us to obtain the incidence
of all forms of ARD in the area. However, based on the
approximate incidence of mesothelioma in this area, we
would expect to find a mean of 6 cases of mesothelioma
per year. The number of non malignant ARD diseases
should be higher, and may not yet have prompted the
patient to seek medical care.
12. Statistical Analysis: a descriptive and inferential
statistics of the variables in the database will be carried
out for the analysis of the information. The exposure pro-
file and the space-time-patient variables of the patients
will be determined. The incidence and mortality rates
adjusted by age, sex and ARD form will be calculated. The
respective Mantel-Haenszel Odds Ratio for the con-
founder variables will be determined, and logistic regres-
sion and survival analysis will be used to complete the
study. The significance level was set at 5%.
The estimate of the underreporting in the cause of
death certification in the mortality statistics of the Cata-
lan Government mortality register will be carried out
based on the analysis of the death bulletins of the cases
that have died during the follow up due to any of the ARD
conditions.
The potential existence of population clusters of cases
in the town of Cerdanyola del Vallès will be studied, since
in this municipality there was an asbestos related factory
until the end of the 1990s. The geographical areas for
cluster analysis will range from 100 to 500 metres, though
this measure will be reviewed in relation to subsequent
inter-case proximity criteria.
13. Ethics: when the first direct contact of the study
investigator with the patient (or his/her family in case of
death previous to the first contact with a research physi-
cian or due to the absence or incapacity of the patient to
answer himself) is established, the project is explained
and the voluntary participation in the study requested.
Also, the objective and characteristics of the study
(Appendix 2) are explained in detail and the signature of
the informed consent form is requested (Appendix 3).
The informed consent form stipulates the basic ethical
considerations with regard to the right to privacy, ano-
nymity, confidentiality, cancellation and information. The
research team agrees to follow the ethical rules of the
accepted practice established in the deontological code of
the Barcelona Official College of Physicians valid since
20/11/2004.
The study has been favourably evaluated by the
Research Committee of the IDIAP Jordi Gol.
Discussion
The main limitation of the study is that ARD is nor a
common descriptor of reported morbidity, nor a com-
mon basic cause of certified death. Also, ARD are under-
reported as work related diseases. Finally, the quality of
the available information can be limited by the long
latency period between exposure and disease, the lack of
an exact measure of asbestos exposure and the memory
bias of the patients and/or relatives, and the different
degree of quality in the information obtained for each
case depending on the different sources consulted.
To overcome these limitations, the research team aims
to awake the awareness of general practitioners to notify
cases. To check duplicities, each case will be matched
against all data bank. Likewise, during the study period a
quality control of the notification with the data of the
Hospital Discharge Report (CMBD) will be established.
Conclusions
The results and conclusions of the study will allow for a
broad range of scientific and academic health and non-
health related activities to unfold within the framework of
health promotion and safety and of primary, secondary
and tertiary disease prevention. Similarly, the experience
and information obtained will allow the research team to
spread this information through scientific papers and
training activities for different technical, managerial and
organisation groups, and to open the way to a future uni-
fied register of ARD.
It is a unique opportunity for the institutions repre-
sented by the members of the research team to increaseRosell-Murphy et al. BMC Public Health 2010, 10:203
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the value of its investigation in the areas of health care
and applied medical research. If the understanding of
ARD, its incidence and prevalence are better known,
higher quality information and data will be followed by a
broader clinical consensus. This in turn will allow for the
development and diffusion of specific clinical guidelines
for ARD within the framework of quality healthcare man-
agement of primary care. The proposal to implement
ARD Specific Follow-up Units will be encouraged, and
the current scientific literature on ARD will increase.
The conclusions of the current study can contribute to
better reporting practices of ARD as a work related con-
dition. This would have social, financial and care benefits
for the patients and their families. In general, it will con-
tribute to minimise the risk of acquiring ARD also by
advising on the hazardous use of poorly preserved
domestic asbestos-containing tools.
Appendix 1
IDENTIFICATION CODE DATE REGIS-
TERED
(1) PATIENT ID
(2) CASE NUMBER:
(3) ORIGIN:
1: HOSPITAL
2: PRIMARY CARE HEALTH CENTRE
3: PRIMARY CARE MANAGEMENT
4: PRIVATE INSURANCE COMPANY
5: HEALTH WORK DEPARTMENT
6: PRIVATE
7: OTHER
(4) ORIGIN DESCRIPTION:
(5) PRIMARY CARE CLINICAL RECORD NUM-
BER:
(6) SEX: 0: MAN; 1: WOMAN
(7) DATE OF BIRTH:
(8) PLACE OF BIRTH:
TOWN: PROVINCE: COUNTRY:
(9) TOWN OF RESIDENCE:
(10) SOURCE OF EXPOSURE:
1.-CERDANYOLA ASBESTOS CEMENT PLANT
2.-OTHER PLANTS (SPECIFY):
3.-VICINITY (SPECIFY)
4.-FAMILY (SPECIFY):
5.-OTHER (SPECIFY):
9.-UNKNOWN
(11) EXPOSURE INTERVAL:
BEGINNING EXPOSURE INTERVAL 1:_____ FINAL
EXPOSURE INTERVAL 1:_____
BEGINNING EXPOSURE INTERVAL 2:_____ FINAL
EXPOSURE INTERVAL 2:_____
(12) SMOKER
0.-NO
1.-YES____ Number Cigarettes/Day:____ During
(Years):____
2.-EX-SMOKER____ Number Cigarettes/
Day:____ During (Years):____
9.-UNKNOWN
(13) DIAGNOSIS DATE:
(14) CONSIDERED WORK-RELATED DISEASE: (0
= NO, 1 = YES, 9 = UNKNOWN)
(15) SYMPTOMS:
1.-ASYMPTOMATIC
2.-PERSISTENT DRY COUGH
3.-RESPIRATORY FAILURE
4.-CANCER SYMPTOMS
9.-OTHER, SPECIFY:
(16) PHYSICAL EXAMINATION: CLUBBING
CRACKLES
(0 = NO, 1 = YES, 9 = UNKNOWN)
(17) IMAGING
1.- X-RAY
2.- CT SCAN
3.- CT SCAN -LUNGS
4.- MRI
5.- ULTRASOUND
6.-OTHER
(18) IMAGES
1.- PLEURAL PLAQUES
2.- PLEURAL THICKENING
3.- ROUNDED ATELECTASIS
4.- PULMONARY FIBROSIS
5.- PARTIAL PLEURAL EFFUSION
6.- MASSIVE PLEURAL EFFUSION.
7.- OTHER (SPECIFY)
(19) PATHOLOGY TECHNIQUES:
1.- BIOPSY
2.- AUTOPSY
3.- CYTOLOGY
4.- OTHER
9.- UNKNOWN
(20) PATHOLOGY RESULT:
(21) LFT:____ FVC:____%   FEV1:____% Tiffenau
Index:____% TLCO:____ %, DATE:____
(22) CLINICAL PROGRESSION
1.-STABLE
2.-DETERIORATION
3.-DEATH
9.-UNKNOWN
(23) DATE OF DEATH
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CARE IN A HEALTH AREA OF BARCELONA PROV-
INCE
Study objective
To know the clinical and epidemiological features of the
people affected by asbestos exposure.
Study procedures
You have clinical features that can be a consequence of
asbestos exposure. If you accept to participate in the
study, you will be assigned to a study doctor who will
carry out a clinical and work history interview and a spe-
cific clinical examination to determine if you might be
affected by asbestos exposure. You might be asked to pro-
vide clinical records and/or diagnostic tests carried out in
the past, to determine when the disease might have
started. It is possible that the doctor requests additional
diagnostic tests to confirm the diagnosis.
At the end of this process you will be informed on
whether you are or not affected by ARD, and if you
should take any measure to improve your health.
Your participation in the study is voluntary, and at any
point you can withdraw from it. If you withdraw there
will not be any consequences regarding your clinical care.
The data collected during the study will be treated as
confidential. In the study lists only your allocated study
number will appear. In the final report of the study, or in
the case of communicating these results to the scientific
community, your identity will remain anonymous. Infor-
mation will be provided, as is anticipated in the article 5
of the Organic Law 5/1992 of Automated Treatment of
Personal Data regulation, regarding the automated treat-
ment of these data, and of the rights of the participants to
consult, modify or delete from the file their personal data.
This study does not provide with any financial compen-
sation, not even the cost of transport to the Health Cen-
tre.
Study researchers: if you have any doubt concerning
this study, or you would like to comment on some aspect
of it, you could phone............................or get in touch with
your general practitioner.
Once you have read this information and clarified pos-
sible doubts, if you want to take part in the study you will
have to sign the informed consent form.
Appendix 3
INFORMED CONSENT FORM
PROSPECTIVE STUDY OF INCIDENCE CASES OF
ASBESTOS RELATED DISEASES IN PRIMARY CARE
IN A HEALTH AREA OF BARCELONA PROVINCE
I...................................................................................................
..(name and surname)
I have read the information leaflet
I have been able to ask questions about the study
I have received enough information on the study
I have spoken to ..................................................(name of
the attending GP)
I understand that my participation is voluntary
I understand that I can withdraw from the study:
1.- When I want
2.- Without having to explain
3.- And it will not have any consequences on my med-
ical care
I freely consent to participate in the study today,
In............................................................day..............month....
.......................... 20......
.................................................................................. ................
....... .................
Name and surnames of the
participant Signature Date
................................................................................ ..................
...... ....................
Name and surnames of the attending
GP Signature Date
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